Company: BIAF
Filing Date: 2025-04-15
Form Type: DRS
Source: 0001641172-25-004915
Chunk: 18

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-15
Form: DRS
Chunk 18
---
                                                                                                                              
 acceptance of our diagnostic tests and therapeutic product candidates, the size and growth of the potential markets for our current 
 diagnostic tests and therapeutic product candidates, and any future diagnostic tests and therapeutic product candidates we may seek 
 to develop, and our ability to serve those markets;                                                                                 |
| ● | the                                                                                                                                 
 successful development of our commercialization capabilities, including sales and marketing capabilities;                           |
| ● | compliance                                                                                                                          
 with government regulations, including environmental, health, and safety regulations and liabilities thereunder;                    |

| ● | the                                                                                                                                
 impact of a health epidemic on our business, our clinical trials, our research programs, healthcare systems, or the global economy 
 as a whole;                                                                                                                        |
| ● | general                                                                                                                            
 instability of economic and political conditions in the United States (“U.S.”), including inflationary pressures, increased        
 interest rates, economic slowdown or recession, and escalating geopolitical tensions;                                              |

| ● | our                                                            
 anticipated uses of net proceeds from our financings;          |
| ● | the                                                            
 increased expenses associated with being a public company; and |
| ● | other                                                          
 factors discussed elsewhere in this prospectus.                |

Many of the foregoing risks and uncertainties, as well as risks and uncertainties that are currently unknown to us, are or may be exacerbated by factors such as the ongoing conflict between Ukraine and Russia, escalating tensions between China and Taiwan, the war in the Middle East, increasing economic uncertainty and inflationary pressures, and any consequent worsening of the global business and economic environment. New factors emerge from time to time, and it is not possible for us to predict all such factors. Should one or more of the risks or uncertainties described in this prospectus or any other filing with the U.S. Securities and Exchange Commission (the “SEC”) occur, or should the assumptions underlying the forward-looking statements we make herein and therein prove incorrect, our actual results and plans could differ materially from those expressed in any forward-looking statements. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

You should read this prospectus and the documents that we reference within it with the understanding that our actual future results, performance, and events and circumstances may be materially different from what we expect.

Website and Social Media Disclosure

We use our websites (www.bioaffinitytech.com, ir.bioaffinitytech.com, www.cypathlung.com and www.Precisionpath.us/) to share Company